BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, Genin C, Sparrow M, Roblin X, Paul S. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev. 2015;14:231-245. [PMID: 25462578 DOI: 10.1016/j.autrev.2014.11.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016;12:570-579. [PMID: 27464484 DOI: 10.1038/nrrheum.2016.123] [Cited by in Crossref: 125] [Cited by in F6Publishing: 102] [Article Influence: 20.8] [Reference Citation Analysis]
2 Michielan A, D’Incà R. Host-microbiome interaction in Crohn’s disease: A familiar or familial issue? World J Gastrointest Pathophysiol 2015; 6(4): 159-168 [PMID: 26600974 DOI: 10.4291/wjgp.v6.i4.159] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
3 Steiner CA, Berinstein JA, Louissaint J, Higgins PDR, Spence JR, Shannon C, Lu C, Stidham RW, Fletcher JG, Bruining DH, Feagan BG, Jairath V, Baker ME, Bettenworth D, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00593-0. [PMID: 34089850 DOI: 10.1016/j.cgh.2021.05.054] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Papp M, Sipeki N, Tornai T, Altorjay I, Norman GL, Shums Z, Roggenbuck D, Fechner K, Stöcker W, Antal-Szalmas P, Veres G, Lakatos PL. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1]. J Crohns Colitis 2015;9:659-68. [PMID: 25968583 DOI: 10.1093/ecco-jcc/jjv087] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
5 Selmi C, Cantarini L, Kivity S, Dagaan A, Shovman O, Zandman-goddard G, Perricone C, Amital H, Toubi E, Shoenfeld Y. The 2014 ACR annual meeting: a bird’s eye view of autoimmunity in 2015. Autoimmunity Reviews 2015;14:622-32. [DOI: 10.1016/j.autrev.2015.03.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
6 Roggenbuck D, Reinhold D, Baumgart D, Schierack P, Conrad K, Laass M. Autoimmunity in Crohn's Disease—A Putative Stratification Factor of the Clinical Phenotype. Elsevier; 2016. pp. 77-101. [DOI: 10.1016/bs.acc.2016.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
7 Selmi C. Autoimmunity in 2015. Clinic Rev Allerg Immunol 2016;51:110-9. [DOI: 10.1007/s12016-016-8576-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Wang H, Demirkan G, Bian X, Wallstrom G, Barker K, Karthikeyan K, Tang Y, Pasha SF, Leighton JA, Qiu J, LaBaer J. Identification of Antibody Against SNRPB, Small Nuclear Ribonucleoprotein-Associated Proteins B and B', as an Autoantibody Marker in Crohn's Disease using an Immunoproteomics Approach. J Crohns Colitis 2017;11:848-56. [PMID: 28204086 DOI: 10.1093/ecco-jcc/jjx019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
9 Jiang W, Li X. Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Mol Diagn Ther 2015;19:141-58. [DOI: 10.1007/s40291-015-0142-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
10 Zhang H, Zeng Z, Mukherjee A, Shen B. Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev Mol Diagn. 2018;18:867-886. [PMID: 30152711 DOI: 10.1080/14737159.2018.1516549] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
11 Yamamoto S, Kinoshita M, Ikegami T, Suzuki S. High-performance liquid chromatographic separation of 8-aminopyrene-1,3,6-trisulfonic acid labeled N-glycans using a functional tetrazole hydrophilic interaction liquid chromatography column. Journal of Chromatography A 2018;1566:44-50. [DOI: 10.1016/j.chroma.2018.06.050] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
12 Däbritz J. GM-CSF and the role of myeloid regulatory cells in the pathogenesis and treatment of Crohn's disease. Mol Cell Pediatr 2015;2:12. [PMID: 26626346 DOI: 10.1186/s40348-015-0024-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
13 Marlicz W, Skonieczna-Żydecka K, Dabos KJ, Łoniewski I, Koulaouzidis A. Emerging concepts in non-invasive monitoring of Crohn's disease. Therap Adv Gastroenterol 2018;11:1756284818769076. [PMID: 29707039 DOI: 10.1177/1756284818769076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
14 Leite-Gomes E, Dias AM, Azevedo CM, Santos-Pereira B, Magalhães M, Garrido M, Amorim R, Lago P, Marcos-Pinto R, Pinho SS. Bringing to Light the Risk of Colorectal Cancer in Inflammatory Bowel Disease: Mucosal Glycosylation as a Key Player. Inflamm Bowel Dis 2021:izab291. [PMID: 34849933 DOI: 10.1093/ibd/izab291] [Reference Citation Analysis]
15 Laass MW, Röber N, Range U, Noß L, Roggenbuck D, Conrad K. Loss and Gain of Tolerance to Pancreatic Glycoprotein 2 in Celiac Disease. PLoS One 2015;10:e0128104. [PMID: 26047356 DOI: 10.1371/journal.pone.0128104] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
16 Day AS, Leach ST, Lemberg DA. An update on diagnostic and prognostic biomarkers in inflammatory bowel disease. Expert Rev Mol Diagn. 2017;17:835-843. [PMID: 28770636 DOI: 10.1080/14737159.2017.1364160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Halligan S, Boone D, Archer L, Ahmad T, Bloom S, Rodriguez-Justo M, Taylor SA, Mallett S. Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review. Health Technol Assess 2021;25:1-66. [PMID: 34225839 DOI: 10.3310/hta25450] [Reference Citation Analysis]
18 Röber N, Noß L, Goihl A, Reinhold D, Jahn J, de Laffolie J, Johannes W, Flemming GM, Roggenbuck D, Conrad K, Laass MW. Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1624-36. [PMID: 28691939 DOI: 10.1097/MIB.0000000000001159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
19 Yamamoto S, Kinoshita M, Suzuki S. Current landscape of protein glycosylation analysis and recent progress toward a novel paradigm of glycoscience research. J Pharm Biomed Anal 2016;130:273-300. [PMID: 27461579 DOI: 10.1016/j.jpba.2016.07.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
20 Ghouri YA, Tahan V, Shen B. Secondary causes of inflammatory bowel diseases. World J Gastroenterol 2020; 26(28): 3998-4017 [PMID: 32821067 DOI: 10.3748/wjg.v26.i28.3998] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Caneparo V, Pastorelli L, Pisani LF, Bruni B, Prodam F, Boldorini R, Roggenbuck D, Vecchi M, Landolfo S, Gariglio M, De Andrea M. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy. Inflamm Bowel Dis. 2016;22:2977-2987. [PMID: 27636380 DOI: 10.1097/mib.0000000000000926] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
22 DeFilippis EM, Longman R, Harbus M, Dannenberg K, Scherl EJ. Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies. Curr Gastroenterol Rep 2016;18:13. [PMID: 26908281 DOI: 10.1007/s11894-016-0487-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
23 Abu-Freha N, Badarna W, Sigal-Batikoff I, Abu Tailakh M, Etzion O, Elkrinawi J, Segal A, Mushkalo A, Fich A. ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation. BMC Gastroenterol 2018;18:153. [PMID: 30342474 DOI: 10.1186/s12876-018-0884-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
24 Liverani E, Scaioli E, Digby RJ, Bellanova M, Belluzzi A. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol 2016; 22(3): 1017-1033 [PMID: 26811644 DOI: 10.3748/wjg.v22.i3.1017] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
25 Pavlidis S, Monast C, Loza MJ, Branigan P, Chung KF, Adcock IM, Guo Y, Rowe A, Baribaud F. I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment. PLoS Comput Biol 2019;15:e1006951. [PMID: 31039157 DOI: 10.1371/journal.pcbi.1006951] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
26 Nataf S. Evolution, immunity and the emergence of brain superautoantigens. F1000Res 2017;6:171. [PMID: 28529699 DOI: 10.12688/f1000research.10950.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
27 Ciccocioppo R, Imbesi V, Betti E, Boccaccio V, Kruzliak P, Gallia A, Cangemi GC, Maffe GC, Vanoli A, Merante S, De Amici M, Falcone C, Klersy C, Corazza GR. The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Study. Dig Dis Sci 2015;60:2327-37. [PMID: 25757448 DOI: 10.1007/s10620-015-3619-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
28 Zhang S, Luo J, Li J, Wu Z, Hu C, Li P, Deng C, Zhang F, Qian J, Li Y. Retrospective evaluation of the clinical utility of serological biomarkers in Chinese patients with inflammatory bowel disease: 2-year clinical experience. Clin Chem Lab Med 2017;55:865-75. [PMID: 27831916 DOI: 10.1515/cclm-2016-0658] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
29 von Stemann JH, Gjærde LK, Haastrup EK, Minculescu L, Brooks PT, Sengeløv H, Hansen MB, Ostrowski SR. Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles. Sci Rep 2021;11:23971. [PMID: 34907183 DOI: 10.1038/s41598-021-01952-6] [Reference Citation Analysis]
30 Marie I, Leroi AM, Menard JF, Levesque H, Quillard M, Ducrotte P. Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev 2015;14:547-54. [PMID: 25661980 DOI: 10.1016/j.autrev.2015.01.018] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
31 Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. Autoimmun Rev. 2017;16:416-426. [PMID: 28212924 DOI: 10.1016/j.autrev.2017.02.013] [Cited by in Crossref: 121] [Cited by in F6Publishing: 116] [Article Influence: 24.2] [Reference Citation Analysis]
32 Clerc F, Novokmet M, Dotz V, Reiding KR, de Haan N, Kammeijer GSM, Dalebout H, Bladergroen MR, Vukovic F, Rapp E, Targan SR, Barron G, Manetti N, Latiano A, McGovern DPB, Annese V, Lauc G, Wuhrer M; IBD-BIOM Consortium. Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases. Gastroenterology 2018;155:829-43. [PMID: 29792883 DOI: 10.1053/j.gastro.2018.05.030] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
33 Schlör A, Holzlöhner P, Listek M, Grieß C, Butze M, Micheel B, Hentschel C, Sowa M, Roggenbuck D, Schierack P, Füner J, Schliebs E, Goihl A, Reinhold D, Hanack K. Generation and validation of murine monoclonal and camelid recombinant single domain antibodies specific for human pancreatic glycoprotein 2. New Biotechnology 2018;45:60-8. [DOI: 10.1016/j.nbt.2018.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Turina MC, Landewé R, Baeten D. Lessons to be learned from serum biomarkers in psoriasis and IBD – the potential role in SpA. Expert Review of Clinical Immunology 2017;13:333-44. [DOI: 10.1080/1744666x.2017.1244004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
35 Toullec L, Batteux F, Santulli P, Chouzenoux S, Jeljeli M, Belmondo T, Hue S, Chapron C. High Levels of Anti-GM-CSF Antibodies in Deep Infiltrating Endometriosis. Reprod Sci 2020;27:211-7. [PMID: 32046390 DOI: 10.1007/s43032-019-00021-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Edwards SJ, Barton S, Bacelar M, Karner C, Cain P, Wakefield V, Marceniuk G. Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study. Health Technol Assess 2021;25:1-138. [PMID: 33783345 DOI: 10.3310/hta25230] [Reference Citation Analysis]
37 Liaskos C, Gkoutzourelas A, Spyrou V, Koutsoumpas A, Athanasiou LV, Amiridis GS, Billinis C, Bogdanos DP. Pancreatic anti-GP2 and anti-Saccharomyces cerevisiae antibodies in ruminants with paratuberculosis: A better understanding of the immunopathogenesis of Crohn's disease. Clin Res Hepatol Gastroenterol 2020;44:778-85. [PMID: 32035824 DOI: 10.1016/j.clinre.2019.12.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Smids C, Horjus Talabur Horje CS, Groenen MJM, van Koolwijk EHM, Wahab PJ, van Lochem EG. The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand J Gastroenterol. 2017;52:1104-1112. [PMID: 28661185 DOI: 10.1080/00365521.2017.1344875] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
39 Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in Neutropenia. J Immunol 2015;195:1341-9. [PMID: 26254266 DOI: 10.4049/jimmunol.1500861] [Cited by in Crossref: 138] [Cited by in F6Publishing: 128] [Article Influence: 19.7] [Reference Citation Analysis]
40 Assan F, Bachelez H. Reply. J Allergy Clin Immunol 2020;146:461-2. [PMID: 32482528 DOI: 10.1016/j.jaci.2020.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Ince MN, Elliott DE. Effective Use of the Laboratory in the Management of Patients with Inflammatory Bowel Diseases. Gastroenterol Clin North Am 2019;48:237-58. [PMID: 31046973 DOI: 10.1016/j.gtc.2019.02.006] [Reference Citation Analysis]
42 Yuan CW, Sun XL, Qiao LC, Xu HX, Zhu P, Chen HJ, Yang BL. Non-SMC condensin I complex subunit D2 and non-SMC condensin II complex subunit D3 induces inflammation via the IKK/NF-κB pathway in ulcerative colitis. World J Gastroenterol 2019; 25(47): 6813-6822 [PMID: 31885422 DOI: 10.3748/wjg.v25.i47.6813] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
43 Cappello M, Morreale GC. The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol. 2016;9:51-62. [PMID: 27656094 DOI: 10.4137/cgast.s38203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Onal IK, Beyazit Y, Altinbas A, Kurt M, Arhan M. Maintenance therapy for Crohn's disease: should it be indefinite? Eur J Gastroenterol Hepatol. 2015; Jul 15. [Epub ahead of print]. [PMID: 26181109 DOI: 10.1097/MEG.0000000000000433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]